Compare Merck & Co., Inc. (MRK) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Merck & Co., Inc. trades at $126.01 (market cap $307.25B), while YieldMax MSTR Option Income Strategy ETF trades at $13.58. The key difference: Merck & Co., Inc. pays a 2.73% dividend while YieldMax MSTR Option Income Strategy ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MRK | MSTY | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $129.52 | $108.80 |
52-Week Low | $77.60 | $11.55 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.
The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.
MSTY trades at $13.12, up 2.34% today, but remains in a bearish technical trend with significant price depreciation year-to-date. The ETF generates high weekly dividend distributions, but these are offset by substantial capital erosion, as highlighted by financial media. Key technical indicators signal selling pressure, with moving averages and oscillators predominantly bearish or neutral.
The outlook is cautious due to structural risks in the covered-call strategy capping upside potential while exposing investors to full downside. High distributions may not be sustainable if funded by return of capital. Investor sentiment is negative, with media reports emphasizing total return losses outweighing dividend income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
